COMPASS Pathways plc Q2 FY2025 earnings call

• Welcomed Justin Gover to the COMPASS Board, leveraging his expertise from GW Pharmaceuticals' Epidiolex launch.
• Announced successful primary endpoint of COMP360 005 trial in treatment-resistant depression (TRD), with statistically significant reduction in depression and clinically meaningful difference vs placebo. Achieved 2 for 2 positive late-stage results in TRD.
• COMP006 Phase III trial is recruiting well, on track to disclose 26-week data in H2 2026. Team working on commercial launch with mental health providers, highlighting patient preference vs SPRAVATO's treatment window.
• Excited about potential for COMP360 in PTSD, finalizing study design; ongoing anorexia study had encouraging efficacy signals but limited statistical power due to small sample and high dropouts.

No detailed product segment financial performance provided in the transcript.

• Cash and cash equivalents at $222M as of end-June, expecting net cash used in operations for 2025 to be $120M-$145M.
• Plan to meet with FDA in Q3 to discuss COMP360 data and explore accelerated filing paths. Submitted application for Commissioner's National Priority Review Voucher.
• COMP006 Phase III trial on track to disclose 26-week data in H2 2026.

• Uncertainties in FDA review process and potential delays in regulatory approval.
• Safety concerns in patient populations like anorexia with higher rates of suicidality, though no imbalance between treatment arms in trials.
• Risks associated with clinical trial outcomes and their impact on regulatory decisions.

Q: Paul Matteis asks about FDA engagement, accelerated paths for filing, and timing of filings.

A: Kabir Nath mentions meeting with FDA in Q3, submitted application for National Priority Review Voucher, and discusses engagement with stakeholders including Congress.

Q: Luis asks about strategic collaborations and readiness for COMP360 delivery.

A: Steve Levine states collaborations with mental health care providers show infrastructure is ready for COMP360 if approved, with SPRAVATO delivery infrastructure aligning.

Q: Gavin asks about 006 enrollment and SPRAVATO delivery settings.

A: Kabir says 006 enrollment is progressing well, Steve Levine notes SPRAVATO is primarily delivered in individual rooms.

Q: Athena Chin asks about National Priority Voucher and eligibility.

A: Kabir confirms submission of the voucher application, stating they meet the criteria including significant unmet medical need and innovative treatment.

Q: Judah asks about consistency of FDA interactions.

A: Kabir states there has been consistent engagement with the FDA's psychiatry division.

Q: Leonid asks about safety, including suicidality and anorexia study safety.

A: Guy Goodwin discusses safety in trials, noting no imbalance in suicidality between arms, and higher suicidality rates in anorexia reflecting the condition's risk.

Q: Sumant asks about NDA timeline and Priority Review program requirements.

A: Kabir says it's premature to speculate on NDA timeline before FDA meeting, and the Priority Review program submission requires a 350-word abstract with no additional Phase III data beyond public domain.